<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-01T02:23:37Z</responseDate><request verb="GetRecord" identifier="oai:riuma.uma.es:10630/37150" metadataPrefix="oai_dc">https://riuma.uma.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:riuma.uma.es:10630/37150</identifier><datestamp>2026-02-03T11:24:33Z</datestamp><setSpec>com_10630_2254</setSpec><setSpec>col_10630_37953</setSpec></header><metadata><oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Fenretinide derivatives act as disrupters of serum Retinol  Binding Protein (sRBP) interactions with Transthyretin  (TTR) and the sRBP Receptor</dc:title>
   <dc:creator>Campos-Sandoval, José Ángel</dc:creator>
   <dc:creator>Redondo, Clara</dc:creator>
   <dc:creator>Kinsella, Gemma</dc:creator>
   <dc:creator>Akos, Pal</dc:creator>
   <dc:creator>Geraint, Jones</dc:creator>
   <dc:creator>Eyre, Gwen</dc:creator>
   <dc:creator>Hirst, Simon</dc:creator>
   <dc:creator>Findlay, John</dc:creator>
   <dc:subject>Vitamina A</dc:subject>
   <dc:subject>Retinol</dc:subject>
   <dc:subject>Retinol-binding protein</dc:subject>
   <dc:subject>Fenretinide</dc:subject>
   <dc:subject>Insulin resistance</dc:subject>
   <dc:subject>Type 2 diabetes</dc:subject>
   <dc:subject>Transthyretin</dc:subject>
   <dc:subject>Retinoids</dc:subject>
   <dc:subject>TR-FRET</dc:subject>
   <dc:subject>SPR</dc:subject>
   <dc:subject>sRBP receptor</dc:subject>
   <dc:description>Serum retinol binding protein (sRBP) is released from the liver as a complex with &#xd;
transthyretin (TTR), a process under the control of dietary retinol. Elevated levels of &#xd;
sRBP may be involved in reducing cellular responses to insulin and in generating, first &#xd;
insulin resistance, then type 2 diabetes, offering a new target for therapeutic attack for &#xd;
these conditions. &#xd;
A series of retinoid analogues were synthesised and examined for their binding to sRBP &#xd;
and their ability to disrupt the sRBP-TTR and sRBP-sRBP receptor interactions. A &#xd;
number inhibit the sRBP-TTR and sRBP-receptor interactions similar to or better than &#xd;
Fenretinide (FEN), presenting a potential novel dual mechanism of action and perhaps &#xd;
offering a new therapeutic intervention against type 2 diabetes and its development.&#xd;
Shortening the chain length of the FEN derivative substantially abolished binding to &#xd;
sRBP, indicating that the strength of the interaction lies in the polyene chain region. &#xd;
Differences in potency against the sRBP-TTR and sRBP-receptor interactions suggest &#xd;
variant effects of the compounds on the two loops of sRBP guarding the entrance of the &#xd;
binding pocket which are responsible for these two protein-protein interactions.</dc:description>
   <dc:date>2025-01-28T09:42:27Z</dc:date>
   <dc:date>2025-01-28T09:42:27Z</dc:date>
   <dc:date>2025-01-23</dc:date>
   <dc:date>2011-05</dc:date>
   <dc:type>journal article</dc:type>
   <dc:type>AM</dc:type>
   <dc:identifier>José Angel Campos-Sandoval, Clara Redondo, Gemma K. Kinsella, Akos Pal, Geraint Jones, Gwen S. Eyre, Simon C. Hirst, and John B. C. Findlay. Fenretinide derivatives act as disrupters of serum Retinol  Binding Protein (sRBP) interactions with Transthyretin  (TTR) and the sRBP Receptor. Journal of Medicinal Chemistry 2011 54 (13), 4378-4387 DOI: 10.1021/jm200256g</dc:identifier>
   <dc:identifier>https://hdl.handle.net/10630/37150</dc:identifier>
   <dc:identifier>10.1021/jm200256g</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:rights>open access</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>ACS Publications</dc:publisher>
</oai_dc:dc>
</metadata></record></GetRecord></OAI-PMH>